Trending NewsTrending NewsNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $40.94 -0.87 (-2.08%) Closing price 04:00 PM EasternExtended Trading$40.72 -0.22 (-0.55%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Roivant Sciences Stock (NASDAQ:ROIV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roivant Sciences alerts:Sign Up Key Stats Today's Range$40.22▼$41.4150-Day Range$32.87▼$41.8152-Week Range$13.81▼$42.50Volume6.53 million shsAverage Volume6.28 million shsMarket Capitalization$29.57 billionP/E RatioN/ADividend YieldN/APrice Target$40.63Consensus RatingModerate Buy Company Overview Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions. Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support. Its portfolio has included treatments and investigational medicines for inflammatory and immune-mediated diseases, as well as other specialty indications. Founded in 2014, Roivant has built partnerships with pharmaceutical companies and research organizations to develop and commercialize products in the United States and international markets. The company is led by Chief Executive Officer Matt Gline and maintains a global biopharmaceutical and drug-development presence.AI Generated. May Contain Errors. Read More Roivant Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreROIV MarketRank™: Roivant Sciences scored higher than 33% of companies evaluated by MarketBeat, and ranked 624th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Roivant Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageRoivant Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Roivant Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($2.00) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -77.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -77.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 5.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.09% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 3.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Roivant Sciences has recently increased by 9.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.68 News SentimentRoivant Sciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 39 news articles for Roivant Sciences this week, compared to 6 articles on an average week.Search Interest10 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows5 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $107,261,258.00 in company stock.Percentage Held by Insiders8.80% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ROIV Stock News HeadlinesRoivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript1 hour ago | seekingalpha.comStock Traders Purchase Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)September 10 at 2:16 AM | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 10 at 1:00 AM | Stansberry Research (Ad)Jefferies Financial Group Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $52.00September 10 at 1:24 AM | americanbankingnews.comHC Wainwright Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $47.00September 10 at 1:24 AM | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares of StockSeptember 2, 2026 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) Insider Sells $653,458.70 in StockAugust 22, 2026 | insidertrades.comMayukh Sukhatme Sells 136,942 Shares of Roivant Sciences (NASDAQ:ROIV) StockAugust 19, 2026 | insidertrades.comSee More Headlines ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $21.70 at the beginning of 2026. Since then, ROIV stock has increased by 88.7% and is now trading at $40.94. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings results on Friday, August, 7th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. The firm earned $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative trailing twelve-month return on equity of 22.94%. Read the conference call transcript. Who are Roivant Sciences' major shareholders? Top institutional investors of Roivant Sciences include California State Teachers Retirement System (2.63%), Assenagon Asset Management S.A. (1.16%), Wellington Management Group LLP (0.37%) and Squarepoint Ops LLC (0.07%). Insiders that own company stock include Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Frank Torti, Daniel Allen Gold, Eric Venker, Keith S Manchester, Richard Pulik, Rakhi Kumar, Jennifer Humes and Melissa B Epperly. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Roivant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/07/2026Today9/10/2026Citigroup’s Biopharma Back to School Summit 20269/10/2026Next Earnings (Estimated)11/09/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ROIV's financial health is in the Green zone, according to TradeSmith. ROIV has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ROIV CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees721Year Founded2014Price Target and Rating Average Price Target for Roivant Sciences$40.63 High Price Target$55.00 Low Price Target$16.50 Potential Upside/Downside-0.8%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.77 million Net Margins-3,534.96% Pretax Margin-3,848.65% Return on Equity-22.94% Return on Assets-21.53% Debt Debt-to-Equity RatioN/A Current Ratio16.72 Quick Ratio16.72 Sales & Book Value Annual Sales$8.26 million Price / Sales3,580.12 Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book5.57Miscellaneous Outstanding Shares722,320,000Free Float658,759,000Market Cap$29.57 billion OptionableOptionable Beta1.12 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ROIV) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThis sub-5 dollar stock operates next to SpaceX and Blue OriginA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
